Structure of ef5 (unlabelled parent compound, from PubChem) — Unlabelled parent compoundPubChem CID 389053

[18F]ef5

Also written as [18F]EF-5; [F-18]EF-5; EF5; F-18 EF5

Radionuclide: F-18 t½ 109.77 min
Modality: PET
Production route: —
Stage: —
Syntheses indexed: 0

Inflammatory disease Glioma and brain tumours Gynaecological cancer Head and neck cancer Prostate cancer Preclinical only, no clinical indication yet Reporter gene imaging Tumour hypoxia

What it is

Compound class: 2-nitroimidazole derivative
Target / mechanism: Bioreductive trapping via nitroreductase-mediated metabolism under low oxygen tension (hypoxia marker) PMID 37161820
Clinical application: Head and neck cancer patients undergoing radiotherapy planning PMID 37161820
Theranostic pair: —

Published syntheses

No synthesis has been parsed for this agent yet.

Need this precursor?We can point you to suppliers for [18F]ef5, or handle the enquiry for you.

Get in touch

Quality control Preliminary - inferred from compound class

Ph. Eur. monograph: not verified No Ph. Eur. check is recorded for this entry.
USP monograph: not verified No USP check is recorded for this entry.

AppearancepHRCP HPLCRCP TLCHPLC UVRadionuclidic (HPGe)Half-lifeActivityEndotoxins (LAL)SterilityFilter integrity

How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); organic-phase radiosynthesis assumed from isotope/compound class, no synthesis data confirming it -> GC residual solvents (preliminary); conventional nucleophilic 18F-fluorination assumed from isotope/compound class, no synthesis data confirming K222 use -> Kryptofix test (preliminary)

Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived

Setting up quality control?We can help you scope the equipment needed to release [18F]ef5.

Get in touch

Notes

Added from reverse module search (stage 6); 5 article(s) with F-18.